The effect of aldose reductase and its inhibition on sugar cataract formation

Peter F. Kador, Yoshio Akagi, Jin H. Kinoshita

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Cataracts associated with diabetes and galactosemia are characterized by their rapid onset and bilateral appearance. These cataracts display similar morphology and histology and have common biochemical mechanisms initiating the cataractous processes. An understanding of these biochemical mechanisms has been aided both by the ability to reproduce these cataracts in various animal models and by the development of potent inhibitors of aldose reductase. This is a US government work. There are no restrictions on its use.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalMetabolism
Volume35
Issue number4 SUPPL. 1
DOIs
StatePublished - Apr 1986

Fingerprint

Aldehyde Reductase
Cataract
Galactosemias
Histology
Animal Models

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The effect of aldose reductase and its inhibition on sugar cataract formation. / Kador, Peter F.; Akagi, Yoshio; Kinoshita, Jin H.

In: Metabolism, Vol. 35, No. 4 SUPPL. 1, 04.1986, p. 15-19.

Research output: Contribution to journalArticle

Kador, Peter F. ; Akagi, Yoshio ; Kinoshita, Jin H. / The effect of aldose reductase and its inhibition on sugar cataract formation. In: Metabolism. 1986 ; Vol. 35, No. 4 SUPPL. 1. pp. 15-19.
@article{3f62e95570ce4c11beb6f4b9b1e88447,
title = "The effect of aldose reductase and its inhibition on sugar cataract formation",
abstract = "Cataracts associated with diabetes and galactosemia are characterized by their rapid onset and bilateral appearance. These cataracts display similar morphology and histology and have common biochemical mechanisms initiating the cataractous processes. An understanding of these biochemical mechanisms has been aided both by the ability to reproduce these cataracts in various animal models and by the development of potent inhibitors of aldose reductase. This is a US government work. There are no restrictions on its use.",
author = "Kador, {Peter F.} and Yoshio Akagi and Kinoshita, {Jin H.}",
year = "1986",
month = "4",
doi = "10.1016/0026-0495(86)90181-2",
language = "English (US)",
volume = "35",
pages = "15--19",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - The effect of aldose reductase and its inhibition on sugar cataract formation

AU - Kador, Peter F.

AU - Akagi, Yoshio

AU - Kinoshita, Jin H.

PY - 1986/4

Y1 - 1986/4

N2 - Cataracts associated with diabetes and galactosemia are characterized by their rapid onset and bilateral appearance. These cataracts display similar morphology and histology and have common biochemical mechanisms initiating the cataractous processes. An understanding of these biochemical mechanisms has been aided both by the ability to reproduce these cataracts in various animal models and by the development of potent inhibitors of aldose reductase. This is a US government work. There are no restrictions on its use.

AB - Cataracts associated with diabetes and galactosemia are characterized by their rapid onset and bilateral appearance. These cataracts display similar morphology and histology and have common biochemical mechanisms initiating the cataractous processes. An understanding of these biochemical mechanisms has been aided both by the ability to reproduce these cataracts in various animal models and by the development of potent inhibitors of aldose reductase. This is a US government work. There are no restrictions on its use.

UR - http://www.scopus.com/inward/record.url?scp=0022633518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022633518&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(86)90181-2

DO - 10.1016/0026-0495(86)90181-2

M3 - Article

C2 - 3083204

AN - SCOPUS:0022633518

VL - 35

SP - 15

EP - 19

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4 SUPPL. 1

ER -